Avandaryl contains a mix of glimepiride and rosiglitazone, 2 oral polygenic disorder medicines that facilitatemanagement glucose levels.

Avandaryl is for individuals with kind two polygenic disorders. This medication isn’t for treating kind one polygenic disorder.

Avandaryl isn’t counseled to be used with endocrine. Taking Avandaryl whereas you’re victimization endocrinemight increase your risk of great heart issues.

Submit your review

Create your own review

Average rating:  
 0 reviews
  • Avandaryl
  • Get emergency medical help if you have signs of an allergic reaction to Avandaryl: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

    Call your doctor at once if you have:

    shortness of breath (even with mild exertion), swelling, rapid weight gain;
    chest pain or heavy feeling, pain spreading to the arm or jaw, nausea, sweating, general ill feeling;
    pale skin, easy bruising or bleeding, weakness;
    upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
    changes in your vision; or
    severe skin reaction - fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.
    Common Avandaryl side effects may include:

    headache; or
    cold symptoms such as stuffy nose, sneezing, sore throat.
  • Individualize dose based on safety, efficacy, and prior therapy; asses the risk versus benefit of initiating with combination therapy versus monotherapy Initial dose: rosiglitazone 4 mg/glimepiride 1 mg orally once a day -Patients receiving a sulfonylurea or rosiglitazone: May consider a starting dose of rosiglitazone 4 mg/glimepiride 2 mg orally once a day -Patients receiving rosiglitazone and glimepiride as individual components: Initial dose is the combination product containing the same dose of each component Dose Titration: Individualize based on glycemic response and safety concerns for each component. -Patients switching from rosiglitazone: Titrate glimepiride after 1 to 2 weeks in increments of no more than 2 mg; following increase, rosiglitazone may be titrated after 1 to 2 weeks -Patients switching from sulfonylurea: Titrate rosiglitazone after 8 to 12 weeks; allow 2 to 3 months to see full effect of increase before further titration Maximum dose: rosiglitazone 8 mg/glimepiride 4 mg